Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are seeing how well the drug FORE8394 works in people with advanced solid tumors, including brain tumors. The people in this study include adults and children with cancers that keep growing or came back even with treatment. Their tumors have mutations (changes or variants) in the BRAF gene.
The purpose of this study is to assess the safety of the investigational treatment REGN4018 alone and in combination with cemiplimab in women with ovarian, peritoneal, or fallopian tube cancer that has come back or gotten worse after previous treatment. REGN4018 is a type of drug called a bispecific antibody: it binds to two specific proteins (MUC16 and CD3) that may be involved in the growth and survival of cancer.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are assessing two different doses of revumenib to give with azacitidine and venetoclax in young people with leukemia. This study includes children, teens, and young adults with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that came back or keeps progressing after treatment.
Researchers want to learn if giving ivosidenib with other drugs is safe and works well in people with advanced cholangiocarcinoma. The people in this study have cholangiocarcinoma that has metastasized (spread) and is inoperable (cannot be removed with surgery). Their tumors have a mutation (change) in the IDH1 gene.
Researchers want to find the best dose of DCC-3116 to give with ripretinib for people with gastrointestinal stromal tumor (GIST). The people in this study have GIST that has spread, even with treatment.
The purpose of this study is to find the best dose of NXC-201 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.
Researchers want to see how well the combination of obinutuzumab, sonrotoclax, and zanubrutinib works against leukemia and lymphoma. The people in this study have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not been treated.
The purpose of this study is to find the highest dose of the investigational drug glofitamab that can be given safely alone or with obinutuzumab in patients with non-Hodgkin lymphoma that came back or continued to grow despite treatment. Glofitamab is a "bispecific antibody" that binds to two different proteins: one found on the surface of cancer cells and one found on the surface of immune cells. Researchers think that glofitamab may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. Both drugs are given intravenously (by vein).
